About The Study: The addition of dapagliflozin, a sodium-glucose cotransporter 2 inhibitor, to standard care for critically ill patients and acute organ dysfunction did not improve clinical outcomes; however, confidence intervals were wide and could not exclude relevant benefits or harms for dapagliflozin.
About The Study: The addition of dapagliflozin, a sodium-glucose cotransporter 2 inhibitor, to standard care for critically ill patients and acute organ dysfunction did not improve clinical outcomes; however, confidence intervals were wide and could not exclude relevant benefits or harms for dapagliflozin.
Corresponding Author: To contact the corresponding author, Fernando G. Zampieri, M.D., Ph.D., email fernando.zampieri@einstein.br.
To access the embargoed study: Visit our For The Media website at this link
(doi:10.1001/jama.2024.10510)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Media advisory: This study is being presented at the Critical Care Reviews Meeting 2024.
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time
Journal
JAMA
Cite Scienmag News
Reid Dalton. (June 14, 2024). Dapagliflozin for critically ill patients with acute organ dysfunction. Scienmag. https://scienmag.com/dapagliflozin-for-critically-ill-patients-with-acute-organ-dysfunction/
Reid Dalton. "Dapagliflozin for critically ill patients with acute organ dysfunction." Scienmag, 14 June 2024, https://scienmag.com/dapagliflozin-for-critically-ill-patients-with-acute-organ-dysfunction/. Accessed 4 September 2026.
Reid Dalton. "Dapagliflozin for critically ill patients with acute organ dysfunction." Scienmag. June 14, 2024. https://scienmag.com/dapagliflozin-for-critically-ill-patients-with-acute-organ-dysfunction/
